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Abstract
Background: The aim of this study was to explore the performance and outcomes for intravascular (IC) versus
surface cooling devices (SFC) for targeted temperature management (TTM) after out-of-hospital cardiac arrest.
Methods: A retrospective analysis of data from the Time-differentiated Therapeutic Hypothermia (TTH48) trial
(NCT01689077), which compared whether TTM at 33 °C for 48 h results in better neurologic outcomes compared
with standard 24-h duration. Devices were assessed for the speed of cooling and rewarming rates. Precision was
assessed by measuring temperature variability (TV), i.e., the standard deviation (SD) of all temperature measurements in
the cooling phase. Main outcomes were overall mortality and poor neurological outcome, including death, severe
disability, or vegetative status.
Results: A total of 352 patients had available data and were included in the analysis; of those, 218 (62%) were
managed with IC. A total of 114/218 (53%) patients with IC and 61/134 (43%) with SFC were cooled for 48 h
(p = 0.22). Time to target temperature (≤ 34 °C) was significantly shorter for patients treated with endovascular
devices (2.2 [1.1–4.0] vs. 4.2 [2.7–6.0] h, p < 0.001), but temperature was also lower on admission (35.0 [34.2–35.6]
vs. 35.3 [34.5–35.8]°C; p = 0.02) and cooling rate was similar (0.4 [0.2–0.8] vs. 0.4 [0.2–0.6]°C/h; p = 0.14) when
compared to SFC. Temperature variability was significantly lower in the endovascular device group when compared
with SFC methods (0.6 [0.4–0.9] vs. 0.7 [0.5–1.0]°C; p = 0.007), as was rewarming rate (0.31 [0.22–0.44] vs. 0.37 [0.29–0.
49]°C/hour; p = 0.02). There was no statistically significant difference in mortality (endovascular 65/218, 29% vs. others
43/134, 32%; p = 0.72) or poor neurological outcome (endovascular 69/218, 32% vs. others 51/134, 38%; p = 0.24)
between type of devices.
Conclusions: Endovascular cooling devices were more precise than SFC methods in patients cooled at 33 °C
after out-of-hospital cardiac arrest. Main outcomes were similar with regard to the cooling methods.
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Introduction
Target temperature management (TTM) is recom-
mended as an effective neuroprotective strategy in
out-of-hospital cardiac arrest (OHCA) patients that
remain comatose following the return of spontaneous
circulations (ROSC), although this is based on low or
very low level of evidence [1]. However, the benefits of
cooling procedures in these patients remain controver-
sial [2] and reduction of body temperature is neither
easy nor without risk. Indeed, hypothermia can result in
a decreased cardiac output and blood pressure, arrhyth-
mias, increased risk of bleeding, hypokalemia, and in-
creased insulin resistance [3]. Despite optimal target and
duration of TTM have been investigated in large ran-
domized clinical trials [4, 5], little is known about the
optimal method to provide TTM to cardiac arrest
patients.
TTM consists of different phases, i.e., induction, main-
tenance, rewarming, and fever control [3]. Over the last
two decades, several cooling systems have been devel-
oped in order to achieve faster induction and more reli-
able temperature maintenance. In this setting, an ideal
device should achieve target temperature quickly, allow
for accurate maintenance and slow, controlled rewarm-
ing as well as avoid post-cooling fever. Initial methods to
initiate TTM included body exposure, cooling pads or
packs as well as the administration of intravenous cold
fluids [6]; although being easy-to-use and cheap, these
methods would produce unpredictable changes and vari-
ations in body temperature and increase the risk of frost-
bite and pulmonary edema [7]. More modern cooling
devices, such as intravascular catheters (IC) or surface
devices (SFC) with cold-water circulating blankets or
hydrogel pads [8–10], provide a more rapid achievement
of target temperature and a longer time within thera-
peutic temperature ranges (i.e., less overcooling and re-
bound hyperthermia), by the use of a temperature
feedback control [11, 12].
Nevertheless, there may be significant differences in
performance and adverse effects between SFC and IC
[13]. Several studies have compared these two different
cooling methods for TTM in post-anoxic brain injury
[13–15]; however, most of them have limited cohorts of
patients and no particular differences on patients’ out-
come were observed between SFC and IC cooling
techniques.
Thus, the aim of this study was to compare SFC
methods with IC methods with regard to cooling preci-
sion, survival, neurological outcome, and adverse event
among OHCA survivors.
Methods
This is a post hoc analysis of data from the
Time-differentiated Therapeutic Hypothermia (TTH48)
trial (NCT01689077), a multicenter, randomized clinical
trial conducted in Europe, which compared whether
prolonged TTM at 33 °C for 48 h results in better neuro-
logic outcome compared with standard 24-h duration
[5]. The study protocol was approved by the Ethics
Committees in each participating center, with written in-
formed consent obtained from the next of kin or a legal
surrogate before randomization. The study recruited 355
patients between February 2013 and June 2016 and dem-
onstrated no significant difference in favorable neuro-
logic outcome at 6 months for those treated during 48 h
(69%) or 24 h (64%) of TTM.
Adult patients, resuscitated from OHCA of a pre-
sumed cardiac cause, older than 17 years and younger
than 80 years, with sustained return of spontaneous cir-
culation for more than 20 consecutive minutes, and with
Glasgow Coma Scale (GCS) score less than 8, were
included in the TTH48 trial. Exclusion criteria have been
reported in the main manuscript [5]; for this study, we
excluded those patients without data on the device used
for TTM or without recording of hourly body
temperature over the study period. All patients were se-
dated and treated with invasive mechanical ventilation.
Other aspects of patient management were decided by
the attending physician according to standard local
practices.
During TTM, three periods were identified: (1) achieve-
ment of target temperature (time from initiation of cool-
ing to first temperature < 34.0 °C), (2) maintenance of
target temperature (time from target temperature to first
temperature ≥ 34.0 °C), and (3) rewarming to 37.0 °C. Core
temperature was mainly measured using urinary, esopha-
geal, or intravascular probes. Temperature was managed
with either SFC or IC methods, according to center pref-
erence, in combination with cold fluids to initiate TTM
and rapidly reach the target temperature. After
randomization, duration of cooling (i.e., 24 or 48 h) was
considered from the time core temperature was 34 °C or
lower. At the end of the 24- or 48-h period, rewarming
was performed at a maximal rate of 0.5 °C/h until a core
temperature of 37.0 °C was reached. Sedation was discon-
tinued at 37.0 °C; the decision to keep devices on patients
to avoid or minimize the occurrence of post-TTM fever
accordingly was performed according to local practices.
Devices were assessed for (1) time from arrest to target
temperature (i.e., < 34.0 °C), (2) time to target temperature
(i.e., time from initiation of cooling to first body
temperature < 34.0 °C), (3) cooling rate (i.e., changes in
temperature from initiation of cooling to first body
temperature < 34.0 °C, expressed as °C/h), (4) number of
patients achieving the target temperature; (5) overcooling
(i.e., at least one body temperature < 32.0 °C), (6) time
spent outside targets (i.e., target is within 32 and 34 °C
since the first body temperature < 34.0 °C until the
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initiation of rewarming; time outside target is expressed as
number of hours or the percentage of hours according to
the duration of cooling), (7) overshoot (i.e., body
temperature after rewarming > 36.0 °C during cooling), (8)
rewarming rate (i.e., changes in temperature between the
initiation of rewarming to the first temperature > 37.0 °C,
expressed as °C/h), and (9) post-TTM fever (i.e., number
of patients with at least one body temperature measure-
ment after rewarming exceeding 38.0 °C). Precision was
assessed by measuring temperature variability (TV), i.e.,
the standard deviation (SD) of all temperature measure-
ments in the cooling phase [16]. Main adverse events were
collected throughout the hospital stay and reported as de-
fined in the main trial [5]. Hyperglycemia was defined as a
blood glucose > 150mg/dL; hypernatremia was defined as
serum sodium > 145mEq/L; hypokalemia was defined as a
serum potassium < 3.5 mEq/L.
Main outcomes were assessed at 180 days and included
overall mortality and poor neurological outcome and de-
fined a Cerebral Performance Categories score (CPC) of 3–
5 (i.e., CPC 1 = alert, able to work and lead a normal life;
CPC 2 = moderate cerebral disability and sufficient cerebral
function for part-time work; CPC 3 = severe cerebral dis-
ability, dependent on others, and impaired brain function;
CPC 4 = coma and vegetative state; CPC 5 = dead or certi-
fied brain dead).
Statistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics 24.0 for Windows. Descriptive statistics were
computed for all study variables. A Kolmogorov–Smir-
nov test was used, and histograms and normal-quantile
plots were examined to verify the normality of distribu-
tion of continuous variables. Data are presented as count
(percentage) or median [25th–75th percentiles]. Differ-
ences between groups (i.e., SFC vs. IC) were assessed
using a Fisher’s exact test for categorical variables and a
Wilcoxon rank test for continuous variables. Data from
repeated measures were analyzed using a two-way Fried-
man ANOVA and differences at each time point ex-
plored by the Dunn’s test. Multivariate regression
analysis was performed to adjust overall mortality and
unfavorable neurological outcome by the same prede-
fined covariates (i.e., trial site, age, gender, initial cardiac
arrest rhythm, time to return of spontaneous circulation,
bystander-initiated life support, duration of cooling), as
suggested in the main trial [5], as well as for those vari-
ables showing a statistical difference in the univariate
analysis (p < 0.1—see Table 1). A p < 0.05 was considered
as statistically significant.
Results
Of the 355 randomized to the trial, 3 were excluded be-
cause of lack of data on body temperature, leaving 352
(99%) patients for the final analysis. Of those, 218 (62%)
were treated with IC and 134 (38%) with SFC. Also, 114/
218 (53%) and 61/134 (46%) patients were cooled for 48
h using IC or SFC, respectively (p = 0.22). Main charac-
teristics of the study population are reported in Table 1.
Additional cooling methods were used in 75/218 (34%)
patients in the IC group (n = 23 SFC; n = 67 cold fluids
with 15 patients receiving both) and in 58/134 (42%,
cold fluids—p = 0.11) in the SFC group.
The mean ± SD temperatures for IC and SFC devices
during the intervention are presented in Figs. 1 and 2,
according to the duration of hypothermia. Main per-
formance results are presented in Table 2. Time to target
temperature was significantly shorter for patients treated
with IC (2.2 [1.1–4.0] vs. 4.2 [2.7–6.0] h; p < 0.001), but
temperature was also lower on admission (35.0 [34.2–
35.6] vs. 35.3 [34.5–35.8] °C; p = 0.02) and cooling rate
was similar (0.42 [0.18–0.81] vs. 0.34 [0.16–0.31]°C/h; p
= 0.08) when compared with others. Temperature vari-
ability was significantly lower in the endovascular device
group when compared with SFC methods (0.6 [0.4–0.9]
vs. 0.7 [0.5–1.0]°C/h; p = 0.007), as was rewarming rate
(0.31 [0.22–0.44] vs. 0.37 [0.29–0.49]°C/h; p = 0.002).
The number of hours outside the therapeutic ranges was
higher for the IC group, although the proportion of
hours outside ranges on the total duration of cooling
was similar between groups. Post-TTM fever was more
frequent in the IC than in the SFC group.
There was no statistically significant difference in mor-
tality (IC = 65/2178, 29% vs. SFC = 43/134, 32%; OR 0.89
[95% CIs 0.57–1.43], p = 0.65; adjusted OR 0.94 [0.48–
1.81], p = 0.84) or poor neurological outcome (IC = 69/
218, 32% vs. SFC = 51/134, 38%; OR 0.65 [0.33–1.25], p
= 0.19; adjusted OR 0.78 [0.41–1.48], p = 0.45) between
the type of devices, regardless of the duration of
hypothermia (Fig. 3 and Table 3). The number of pa-
tients with at least one adverse event was similar be-
tween groups (Table 3); arrhythmias and hypokalemia
were more frequent in the IC group, while hypernatre-
mia was more frequent in the SFC group.
Discussion
In this study evaluating the database of a randomized
clinical trial, we evaluated the differences in
temperature control between IC and SFC methods to
achieve TTM among survivors of OHCA. The use of
IC was associated with a similar time to target
temperature (i.e., speed of cooling), a lower
temperature variability during the maintenance phase,
a slower rewarming rate, but more frequent
post-TTM fever than SFC devices. No differences in
mortality or poor neurological outcome between the
two methods were observed. Also, the rate of adverse
events was similar between groups.
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The optimal cooling technique to deliver TTM after
OHCA remains still unknown. Although international
guidelines recommend to use devices with a continuous
temperature feedback control (TFC) in this setting, to
minimize the risk of overcooling and to provide a more
stable control of target temperature [17], invasive
methods using IC with TFC are the most precise cooling
techniques to provide TTM, even when compared to
external SFC devices [13]. However, whether this might
influence patients’ outcome, it is still debated. The
choice of one or the other method is usually driven by
different considerations such as precision, workload for
nurses, costs, and the risk/benefit ratio. External SFC
methods are applied around the torso and limbs and can
adequately induce and maintain TTM in OHCA patients
[18]; however, they also require more nursing attention,
are frequently associated with shivering, may reduce
overall access to the patient, and induce some skin dam-
age [19]. Intravenous cooling with IC devices are effect-
ive for TTM in OHCA patients, but they need a trained
physician to insert the catheter into the large vein and
may be associated with a higher risk of infection and
bleeding [19].
Assessment of IC and SFC devices has already been
performed in large animal models, showing a faster cool-
ing rate for IC when compared with others [20]. In
humans, results are more controversial. Ferreira et al.
showed that the time to target temperature was faster
and the rewarming rate lower in IC-treated patients
when compared with the SFC group [21]. On the oppos-
ite, Tømte et al. observed no differences in cooling rates,
post-TTM fever, and the occurrence of main adverse
events between SFC and IC cooling methods [22]. Simi-
lar results on cooling rate and the occurrence of over-
cooling were observed in another study, although target
temperature maintenance was more stable in the IC
group than in SFC-cooled patients [23]. Less fluctuation
of body temperature during the maintenance phase with
the use of IC devices when compared with SFC methods
was observed also in other studies [7, 24]. In our study,
the cooling rates were similar between groups. However,
there was a higher number of patients in the SFC group
receiving also cold fluids; administration of cold fluids is
actually the most common and rapid method to induce
hypothermia, especially when administered in the
pre-hospital setting, although some concerns on its
effectiveness and potential harms exist [25], and may
have contributed to faster-cooling rates in the SFC
group. We observed a lower TV in the IC-treated pa-
tients than in the SFC group. Despite this finding might
again underline a higher precision to maintain the target
temperature using IC, TV was somewhat higher in pa-
tients with favorable than unfavorable neurologic out-
come [16] and might suggest intact thermoregulatory
pathways that aim to restore a body temperature close
to 37.0 °C rather than a target to optimize TTM. The dif-
ference in TV was so limited (< 0.1 °C) between groups
that one may argue whether this can translate in
Table 1 Characteristics of included patients, according to the
cooling method. Data are expressed as count (%) or median
(25th–75th percentiles)
IC (n = 218) SFC (n = 134)
Demographic characteristics
Age, years 61 [53–53] 63.5
[55–70]€
Male gender, n (%) 189 (87%) 104 (78%)*
Weight, kg 85 [75–95] 80 [75–90]*
Previous neurologic disability, n (%) 6 (3%) 4 (3%)
Medical history
Previous myocardial infarction, n (%) 30 (14%) 24 (18%)
Previous PCI or CABG, n (%) 27 (12%) 28 (21%)€
Previous cardiac arrest, n (%) 1 (0%) 2 (1%)
Chronic heart failure, n (%) 9 (4%) 9 (7%)
Chronic obstructive pulmonary disease, n
(%)
13 (6%) 11 (8%)
Liver cirrhosis, n (%) 2 (1%) 1 (1%)
Chronic renal failure with dialysis, n (%) 2 (1%) 0 (0%)
Diabetes mellitus, n (%) 39 (18%) 24 (18%)
Immunocompromised, n (%) 3 (1%) 0 (0%)
Previous stroke, n (%) 13 (6%) 13 (10%)
Arrest characteristics
Home location, n (%) 107 (49%) 85 (63%)*
Witnessed, n (%) 199 (91%) 124 (93%)
Bystander initiated CPR, n (%) 178 (82%) 115 (86%)
Shockable rhythm, n (%) 196 (90%) 116 (87%)
Time to return of spontaneous
circulation, min
21 [15–30] 20 [16–26.8]
Mechanical chest compression, n (%) 56 (26%) 34 (25%)
Adrenaline, n (%) 135 (62%) 86 (64%)
Amiodarone, n (%) 93 (43%) 52 (39%)
Pre-ICU orotracheal intubation, n (%) 206 (94%) 137 (97%)
Pre-ICU cooling, n (%) 88 (40%) 59 (44%)
Coronary angiography, n (%) 184 (84%) 107 (80%)
PCI, n (%) 84 (39%) 61 (46%)
Characteristics on ICU admission
Sedation, n (%) 216 (99%) 133 (99%)





IC intravascular catheter, SFC surface cooling, PCI percutaneous coronary
intervention, CABG coronary artery bypass graft, ICU intensive care unit, CPR
cardiopulmonary resuscitation. $p < 0.001; *p < 0.05; €p < 0.1
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clinically relevant benefits on patients’ outcome.
Moreover, the proportion of time outside therapeutic
ranges was similar between groups, suggesting that
despite a more stable core temperature, the effective-
ness of the devices to maintain the body temperature
in the selected target was similar. Finally, rewarming
rate was lower in the IC group, although the differ-
ence was numerically small (i.e., 0.06 °C). There are
no clinical data suggesting a critical cut-off for harm
of excessively rapid rewarming after TTM in OHCA
survivors, although high rewarming rate, exceeding
0.5 °C, might be associated with a higher risk of poor
neurological outcome (71% vs. 52%) than slower
rewarming [26]. As both cooling devices in our study
had rewarming rate below this cut-off of 0.5C°/h, it is
hard to conclude that the minimal differences in
rewarming rate observed in this cohort can result in
any clinically relevant result.
Previous studies have also reported more frequent
complications with the IC than with SFC devices, al-
though these findings remain discordant and might be
due to chance or selection bias among different studies.
In one study, infectious and cardiovascular complica-
tions were similar between IC and SFC [7]. In a large
cohort, shivering, electrolyte disturbances, and arrhyth-
mias were also similar between IC and SFC devices [15].
In a small RCT, pneumonia and ischemic stroke were
more frequent in the SFC group, while the occurrence of
significant arrhythmias and renal failure was higher in
the IC group [11]. In a matched-control analysis, the use
of IC was associated with a greater incidence of sepsis
[27]. In another study, an increase in bleeding was ob-
served in the IC group (14% versus 2%, p = 0.11) [14].
We also observed relatively similar occurrence of ad-
verse events between IC and SFC devices in our study,
except for more frequent arrhythmias and hypokalemia
Fig. 1 Temperatures in the intravascular catheter (IC) and surface cooling (SFC) groups until 72 h after achieving target temperature, with T0
defined as the time target temperature was reached. Duration of cooling = 24 h. Values are presented as mean ± 2 SDs
Fig. 2 Temperatures in the intravascular catheter (IC) and surface cooling (SFC) groups until 72 h after achieving target temperature, with T0
defined as the time target temperature was reached. Duration of cooling = 48 h. Values are presented as mean ± 2 SDs
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Table 2 Performance findings on body temperature between the two groups. Data are expressed as count (%) or median (25th–
75th percentiles). Number of hourly available temperature at normothermia = number of hourly recorded body temperature
available after normothermia has been reached
IC (n = 218) SFC (n = 134)
Admission temperature, °C 35.0 [34.2–35.6] 35.3 [34.4–35.8]*
Time from Arrest to Temperature < 34 °C, hours 4.9 [3.9–6.5] 6.8 [5.1–9.0]$
Time to Temperature < 34 °C, hours 2.2 [1.1–4.0] 4.4 [2.8–7.0]$
First recorded Temperature < 34 °C, °C 33.8 [33.3–33.9] 33.6 [33.2–33.8]
Cooling Rate, °C/h 0.42 [0.19–0.81] 0.34 [0.16–0.61]
Duration of cooling, hours 40 [27–51] 28 [24–48] $
During cooling
- Mean temperature, °C 33.4 [33.1–33.8] 33.5 [33.2–33.8]
- Minimum temperature, °C 32.8 [32.5–33.0] 33.6 [32.3–32.9]*
- Maximal temperature, °C 35.2 [34.3–35.9] 35.5 [34.9–36.0]*
Temperature Variability during cooling, °C 0.65 [0.40–0.88] 0.69 [0.54–0.93]*
Patients never achieving target temperature, n (%) 16 (7) 6 (4)
Temperature outside targets, hours 7 [2–20] 5 [3–8]*
Temperature within targets, % 18 [5–36] 15 [7–27]
Patients with overcooling, n (%) 30 (14) 14 (10)
Patients with overshoot, n (%) 52 (24) 39 (29)
Early interruption of cooling, n (%) 8 (6) 6 (3)
Time to Normothermia, hours 9.3 [6.8–13.6] 7.5 [6.0–10.0]*
Rewarming Rate, °C/h 0.31 [0.22–0.44] 0.37 [0.29–0.49]*
Number of hourly available temperature at normothermia, hours 48 [24–81] 39 [18–54]
Max temperature reached during normothermia, °C 38.2 [37.8–38.6] 38.0 [37.6–38.4]
Post-TTM Fever, n (%) 137 (63) 67 (50)*
IC intravascular catheter, SFC surface cooling, TTM targeted temperature management. $p < 0.001; *p < 0.05; €p < 0.1
Fig. 3 Mortality and unfavorable neurological outcome in the intravascular catheter (IC) and surface cooling (SFC) groups, according to the
duration of cooling
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in the IC group, probably due to a larger proportion of
patients being cooled for 48 h. Also, post-TTM fever was
more frequent in the IC group, which is in contrast with
previous publications [22, 23]. These findings might be
potentially explained either by a higher number of re-
corded temperatures in the IC group (i.e., more data
available which translates in a higher probability to
detect fever) or by the early removal of the endovascular
system, because of the risk of infection and bleeding,
which would have exposed these patients to a less accur-
ate temperature control in the post-cooling phase. Im-
portantly, as no specific data on shivering control,
sedation policies, and/or catheter removal were reported,
we could not specifically analyze the determinants of
post-TTM fever in this cohort. However, the safety pro-
file of both cooling systems looks comparable, and the
selection of one strategy over the other might be influ-
enced by the potential benefits on mortality and neuro-
logical recovery.
Together with some advantages in the TTM delivery
for IC over SFC devices and a similar safety profile, no
significant differences in patients’ outcome were ob-
served between groups. Whether our study is simply
underpowered to show any statistical significance be-
tween the methods or if this difference is related to an
imbalance between IC and SFC (i.e., more patients
cooled for 48 h, less arrest occurring at home, and a less
significant difference in outcome when adjusted for con-
founders), it is impossible to conclude from our data. In
a recent post hoc analysis of a large RCT including 934
patients [15], mortality and poor neurological outcome
was lower in the IC group when compared with SFC de-
vices (46.3% vs. 50.0% and 49.0% vs. 54.3%, respectively).
Other studies also showed a non-significant reduction in
mortality or poor neurological outcome in the IC group
of around 5–10% [7, 14, 22, 23], although this was not
consistent in another study [27, 28]. Importantly, this
might be explained by chance, selection bias or by differ-
ent case-mixes (i.e., large referral centers with PCI facil-
ities tend to use endovascular cooling techniques).
Moreover, SFC devices are not entirely comparable as
they include a wide range of devices, from simple ice
bags to sophisticated machines with automatic TFC
using blankets containing circulating coolant, and these
differences may also impact on outcome in this setting.
In one study, Shinada et al. observed that the use of SFC
with self-adhesive, hydrogel-coated pads gel-circulating
and TFC was associated with a lower mortality and poor
neurological outcome (20% vs. 27% and 28% vs. 45%,
respectively) than conventional SFC using blankets [18].
In another small RCT, Heard et al. showed that
hydrogel-coated pads gel-circulating and TFC had a
lower proportion of patients with poor neurological out-
come (39% vs. 47%) than the use of cooling blankets and
ice [11]. As such, future studies comparing IC and SFC
with TFC are needed to better understand the impact of
such cooling strategies on patients’ outcome. Also, a sys-
tematic review and meta-analysis of the existing litera-
ture might help to further quantify the relevance of
cooling methods on mortality and neurological outcome
of OHCA survivors.
This study has also several limitations. First, selection
bias related to the use of different cooling methods in
the different participating centers may account for some
of the differences between groups. In particular, it is im-
possible to consider whether a real choice or equipoise
existed between IC and SFC at the time point of treat-
ment selection for those centers where both devices
were available. Moreover, some centers had only of the
two devices available so that differences in outcome, des-
pite similar cooling times, might be influenced by the
“site” effect, although this was considered into the ad-
justed analysis. Second, the study was not powered to
detect differences in clinical outcome. Third, the accur-
acy of intervals, such as time to cooling or target
Table 3 Temperature analyses and outcomes of included
patients, according to the methods of cooling. Data are
expressed as count (%) or median (25th–75th percentiles)
IC (n = 218) SFC (n = 134)
Primary outcome
CPC 3–5 at 6 months 69 (32%) 51 (38%)
Secondary outcomes
Mortality at 6 months 65 (29%) 43 (32%)
Adverse events
Any adverse event 203 (93%) 118 (88%)
Pneumonia 106 (49%) 56 (42%)
Other infections 75 (34%) 54 (40%)
Any bleeding 24 (11%) 16 (12%)
RBC transfusion 20 (9%) 15 (11%)
Seizure/myoclonus localized 27 (12%) 18 (13%)
Seizure/myoclonus globalized 39 (18%) 25 (19%)
Severe circulation failure 13 (6%) 15 (11%)€
Arrhythmias 105 (48%) 50 (37%)*
Severe (VT/VF or unstable despite
treatment)
21 (10%) 19 (14%)
New cardiac arrest requiring CPR 7 (3%) 5 (4%)
Renal replacement therapy 13 (6%) 14 (10%)
Hyperglycemia 169 (78%) 113 (83%)
Hypernatremia 21 (10%) 24 (18%)*
Hypokalemia 88 (40%) 38 (28%)*
Resource use
ICU length of stay (days) 5 [3–7] 6 [3–9]
IC intravascular catheter, SFC surface cooling, RBC red blood cells. $p < 0.001;
*p < 0.05; €p < 0.1
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temperature, might be unreliable since this information
may be subject to reporting or measurement errors.
Forth, different sites of temperature measurement were
used, which may have led to a measurement bias. Also,
brain temperature typically exceeds body temperature by
0.5 to 2.0 °C after an acute brain injury, so that measur-
ing peripheral temperature is a poor indicator of
temperature control within the cerebral tissue [28]. Fifth,
this was not a randomized study primarily investigating
performance of cooling devices; as such, the risk of bias
is high and any association found should be cautiously
interpreted. Also, we did not report about the type of
devices (i.e., different types of endovascular devices or
the proportion of cold-water circulating blankets vs.
hydrogel pads in the surface cooling group), and this
may contribute to a significant variability in TTM effect-
iveness and precision within the groups. Moreover, some
differences between groups (i.e., arrest location) were
not considered in the adjusted analysis of outcomes.
Finally, we have analyzed cooling devices by categories
rather than comparing individual IC or SFC devices and
the heterogeneity among different systems can also
account for some observed differences between groups.
Conclusions
In this study, endovascular cooling devices were more pre-
cise than SFC methods in patients cooled at 33 °C after
out-of-hospital cardiac arrest. Main outcomes (i.e., mortal-
ity and neurological outcome) were similar with regard to
the cooling methods, which suggest no clinically relevant
differences in this setting.
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